Table 2 Multivariate analysis of clinical prognostic factors for the development of prostate cancer bone metastasis and prostate cancer-specific death in the radical retropubic prostatectomy tissue microarray cohort
From: Nuclear iASPP may facilitate prostate cancer progression
Bone metastases | Prostate cancer death | |||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
All prostate cancer cases | ||||
pT stage | 1.92 (0.96–3.85) | 0.065 | 4.33 (1.75–10.69) | 0.001 |
pN stage | 1.58 (0.88–2.86) | 0.129 | 1.96 (1.05–3.67) | 0.035 |
PSA | 1.01 (0.99–1.02) | 0.505 | 1.00 (0.99–1.02) | 0.828 |
Gleason group | 2.32 (1.55–3.47) | <0.001 | 1.95 (1.23–3.10) | 0.004 |
Nuclear iASPP expression | 0.97 (0.47–1.98) | 0.925 | 1.82 (0.91–3.66) | 0.092 |
Cytoplasmic iASPP expression | 0.98 (0.49–1.94) | 0.948 | 1.26 (0.63–2.53) | 0.508 |
Gleason 7 prostate cancer cases | ||||
pT stage | 6.36 (0.91–44.28) | 0.062 | 3.72 (0.74–18.63) | 0.110 |
pN stage | 1.18 (0.31–4.54) | 0.813 | 1.13 (0.36–3.60) | 0.833 |
PSA | 1.04 (1.0–1.09) | 0.055 | 0.99 (0.94–1.04) | 0.576 |
Nuclear iASPP expression | 3.81 (0.80–18.1) | 0.093 | 3.72 (1.10–12.61) | 0.035 |
Cytoplasmic iASPP expression | 0.56 (0.11–3.0) | 0.501 | 0.53 (0.12–2.36) | 0.403 |
Gleason ≥8 prostate cancer cases | ||||
pT stage | 3.84 (0.91–16.18) | 0.066 | 8.20 (0.91–73.57) | 0.06 |
pN stage | 0.70 (0.19–2.53) | 0.585 | 1.84 (0.46–7.33) | 0.389 |
PSA | 1.01 (0.99–1.03) | 0.56 | 1.00 (0.98–1.02) | 0.766 |
Nuclear iASPP expression | 0.70 (0.16–3.13) | 0.639 | 0.22 (0.03–1.47) | 0.119 |
Cytoplasmic iASPP expression | 4.58 (1.24–16.98) | 0.023 | 8.17 (1.46–45.73) | 0.017 |
